Pfizer, BioNTech rebuff CureVac's 'groundless' patent infringement claims against COVID-19 shot Comirnaty

Pfizer and BioNTech aren’t playing sitting duck in the COVID-19 vaccine patent litigation that German mRNA specialist CureVac has brought.

After joining forces to develop the massively successful COVID shot, Comirnaty, Pfizer and BioNTech are now facing what they call “threats of a groundless patent infringement suit by a company, CureVac, who has been unable to bring to market any product to help in the fight against COVID-19,” the partners said in a complaint filed Monday in the U.S. District Court for the District of Massachusetts.